Boltz raises $110 million for AI models that design drug molecules
The MIT spinout's Series A was led by Bessemer Venture Partners. It says six of the world's 20 largest pharma companies use its platform.
Key takeaways
- Boltz raised $110 million in a Series A led by Bessemer Venture Partners; it did not disclose a valuation.
- Existing backers such as Andreessen Horowitz invested again, and new investors including Greycroft and Benchling joined.
- Boltz builds AI models that predict how drugs and proteins bind and propose new molecules.
- The company says six of the 20 largest pharma companies, including Pfizer and GSK, use its platform.
- Tech.eu calls Boltz London-based, while Wowtale says it is based in Cambridge, Massachusetts.
Boltz, an AI drug-discovery startup that began at MIT, has raised $110 million in a Series A round led by Bessemer Venture Partners, the company said. The round was also reported by Tech.eu and Wowtale.
The company says all its existing backers invested again, among them Andreessen Horowitz, Amplify Partners and Zetta Venture Partners, as well as Obvious Ventures. Greycroft and F-Prime Capital are among the new investors, alongside Hummingbird and Benchling, Boltz says, and Andrew Hedin and Byron Deeter of Bessemer are joining Boltz. Tech.eu reports that Nvidia also invested earlier this year. The startup did not disclose a valuation, Wowtale reports. The new round follows a $28 million seed round in January, according to Wowtale; Tech.eu says the seed came at the start of the year.
What does Boltz make?
Its models predict the shape a protein and a drug candidate take when they bind, gauge the strength of that binding and suggest new molecules aimed at a chosen target, Tech.eu reports. While at MIT, its co-founders released open-source models that matched closed models such as DeepMind's AlphaFold3, according to Tech.eu. Wowtale says the first, Boltz-1, claimed accuracy at the level of AlphaFold 3 for predicting the structure of complexes.
In June, Boltz launched BoltzMol-1 and BoltzProt-1, its first proprietary models. With these models, Boltz says, it found promising small molecules and created protein binders for most of the hard targets it tried. Wowtale notes that Boltz has not disclosed the targets or specific results.
Anyone can still download the open models at no cost. Revenue comes from partnerships, Tech.eu reports, and from the proprietary models and Boltz Lab, the service that runs them, which is priced by usage in "molecular tokens," Wowtale reports. Boltz says paying customers' token use is up 50-fold since June; Wowtale notes it did not split that growth between its proprietary and open models. Its customers include Pfizer, GSK, Takeda and BMS, and in total six of the 20 biggest drugmakers in the world, according to Boltz.
Where is Boltz based?
Reports describe its base differently. Tech.eu calls Boltz London-based and says it employs 40 AI researchers in the King's Cross area. Wowtale describes it as a public benefit corporation based in Cambridge, Massachusetts. Boltz itself says its team has grown to 40 scientists and engineers.
What will the money be used for?
Boltz says the funding will go into compute and data, meeting demand from its partners and growing its team. "Our long-term goal remains a world where a scientist can go from a therapeutic hypothesis to a human-ready molecule without leaving their computer," the company said.
Wowtale notes that Boltz's round is small next to some rivals': Chai Discovery raised $400 million in July and that Isomorphic Labs raised $5 billion this week, and says Andreessen Horowitz has flagged pharma companies' own AI pipelines and frontier AI labs with large compute budgets as risks for Boltz.
Questions readers are asking
Who led Boltz's funding round?
Bessemer Venture Partners led the $110 million Series A; existing backers such as Andreessen Horowitz also invested.
How does Boltz make money?
Its open models are free, but it charges for proprietary models and its Boltz Lab platform, priced by usage in molecular tokens, Wowtale reports.
Has Boltz produced a drug?
Boltz has not announced a drug candidate of its own; Wowtale notes its announcement focuses on supplying models to scientists. Boltz says its models found hits and designed binders for most targets it tried, but has not disclosed the targets or results.
Sources
- #boltz
- #funding
- #drug-discovery
- #series-a
- #startups
Get the day's top AI & tech stories on WhatsApp: Follow the NextFish channel
Get stories like this every morning.
Related
AI Startups2 min
Isomorphic Labs raises $5 billion to push AI-designed drugs toward trials
The London-based Alphabet spinout led by Demis Hassabis has now raised more than $7.7 billion. It has not yet put a drug into clinical trials.
Chips & Infra2 min
UK government funds back AI chip startup Fractile in £500m-plus round
Sovereign AI and the British Business Bank joined Fractile's Series C, which the government says values the inference chip designer at over £5 billion.